ESR1 and breast carcinoma: Based on the etiological role of 17-β-estradiol (E2) in the development and progression of breast cancer, blockade of the E2 signal is utilized as a therapeutic strategy to treat estrogen receptor (ER)-positive breast cancers, which constitutes about 75% of breast cancer cases.